State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao, 999078, China.
Chin J Integr Med. 2019 Oct;25(10):723-727. doi: 10.1007/s11655-019-2708-4. Epub 2019 Nov 28.
Ischemic stroke accounts for the majority of all strokes and has been primary causes of long-term disability and mortality in worldwide. Mesenchymal stem cell (MSC) therapy suggests significantly improved effects on neurological functional outcome, neurogenesis, angiogenesis, blood-brain barrier permeability, inflammatory injury, neuroprotection and so on, following stroke. However, the occurrence of adverse effects results in restriction of the therapy. Chinese medicine accumulates abundant clinical experiences on stroke for over two thousand years, and some formulae and active ingredients of Chinese medicines have presented obvious efficacies in clinical treatment. Therefore, based on Chinese medicine theory, we provide some ideas of screening agents for combination treatment of Chinese medicines and MSC for ischemic stroke, and summarize the potentials of Chinese medicines in MSC treatment and analyze the feasibilities of Chinese medicines against side effects of MSC therapy. Consequently, we propose Chinese medicines combing with MSC should be a promising approach to clinical stroke treatment in future.
缺血性脑卒中占所有脑卒中的大部分，是全世界长期残疾和死亡的主要原因。间充质干细胞（MSC）治疗表明，在脑卒中后对神经功能结局、神经发生、血管生成、血脑屏障通透性、炎症损伤、神经保护等具有显著改善作用。然而，不良反应的发生限制了该治疗方法的应用。中医药在治疗脑卒中方面积累了两千多年的丰富临床经验，一些中药方剂和有效成分在临床治疗中表现出了明显的疗效。因此，我们基于中医药理论，为中药与 MSC 联合治疗缺血性脑卒中提供了一些筛选药物的思路，并总结了中药在 MSC 治疗中的潜力，分析了中药对抗 MSC 治疗副作用的可行性。因此，我们提出中药与 MSC 联合应用可能是未来临床脑卒中治疗的一种有前途的方法。
